James C Yao

Summary

Affiliation: The University of Texas
Country: USA

Publications

  1. ncbi request reprint A phase I study of imatinib, dacarbazine, and capecitabine in advanced endocrine cancers
    Daniel M Halperin
    Department of Gastrointestinal Medical Oncology, The University of Texas M, d, Anderson Cancer Center, Houston, Texas, USA
    BMC Cancer 14:561. 2014
  2. doi request reprint Accelerated approval and breakthrough therapy designation: oncology drug development on speed?
    James C Yao
    Department of Gastrointestinal Medical Oncology, Investigational Cancer Therapeutics, and Biostatistics, The University of Texas MD Anderson Cancer Center, Houston, Texas 77030, USA
    Clin Cancer Res 19:4305-8. 2013
  3. pmc Targeted therapies in neuroendocrine tumors (NET): clinical trial challenges and lessons learned
    James C Yao
    The University of Texas MD Anderson Cancer Center, Houston, Texas 77030, USA
    Oncologist 18:525-32. 2013
  4. doi request reprint Everolimus in advanced pancreatic neuroendocrine tumors: the clinical experience
    James C Yao
    Departments of Gastrointestinal Medical Oncology and Surgical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA
    Cancer Res 73:1449-53. 2013
  5. pmc Evolving diagnostic and treatment strategies for pancreatic neuroendocrine tumors
    Matthew H Kulke
    Dana Farber Cancer Institute, Boston MA, USA
    J Hematol Oncol 4:29. 2011
  6. ncbi request reprint One hundred years after "carcinoid": epidemiology of and prognostic factors for neuroendocrine tumors in 35,825 cases in the United States
    James C Yao
    Department of Gastrointestinal Medical Oncology, Unit 426, The University of Texas M D Anderson Cancer Center, 1515 Holcombe Blvd, Houston, TX 77030, USA
    J Clin Oncol 26:3063-72. 2008
  7. ncbi request reprint Clinicopathologic behavior of gastric adenocarcinoma in Hispanic patients: analysis of a single institution's experience over 15 years
    James C Yao
    Department of Gastrointestinal Medical Oncology, Unit 426, The University of Texas M D Anderson Cancer Center, 1515 Holcombe Blvd, Houston, TX 77030, USA
    J Clin Oncol 23:3094-103. 2005
  8. doi request reprint Chromogranin A and neuron-specific enolase as prognostic markers in patients with advanced pNET treated with everolimus
    James C Yao
    Department of Gastrointestinal Medical Oncology, The University of Texas M D Anderson Cancer Center, 1515 Holcombe Boulevard, Box 426, Houston, Texas 77030, USA
    J Clin Endocrinol Metab 96:3741-9. 2011
  9. ncbi request reprint Clinical and in vitro studies of imatinib in advanced carcinoid tumors
    James C Yao
    Department of Gastrointestinal Medical Oncology, The University of Texas M D Anderson Cancer Center, Houston, Texas 77030, USA
    Clin Cancer Res 13:234-40. 2007
  10. pmc Efficacy of RAD001 (everolimus) and octreotide LAR in advanced low- to intermediate-grade neuroendocrine tumors: results of a phase II study
    James C Yao
    Department of Gastrointestinal Medical Oncology, Unit 426, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Blvd, Houston, TX 77030, USA
    J Clin Oncol 26:4311-8. 2008

Collaborators

Detail Information

Publications73

  1. ncbi request reprint A phase I study of imatinib, dacarbazine, and capecitabine in advanced endocrine cancers
    Daniel M Halperin
    Department of Gastrointestinal Medical Oncology, The University of Texas M, d, Anderson Cancer Center, Houston, Texas, USA
    BMC Cancer 14:561. 2014
    ..Pre-clinical studies have suggested potential activity of imatinib in these tumors. We therefore sought to establish a safe, novel treatment regimen combining imatinib with cytotoxic chemotherapy for future study in endocrine cancers...
  2. doi request reprint Accelerated approval and breakthrough therapy designation: oncology drug development on speed?
    James C Yao
    Department of Gastrointestinal Medical Oncology, Investigational Cancer Therapeutics, and Biostatistics, The University of Texas MD Anderson Cancer Center, Houston, Texas 77030, USA
    Clin Cancer Res 19:4305-8. 2013
    ..Here, we consider the inherent limitations of smaller studies and discuss the strategies for hastening oncology drug development while maintaining high-efficacy standards...
  3. pmc Targeted therapies in neuroendocrine tumors (NET): clinical trial challenges and lessons learned
    James C Yao
    The University of Texas MD Anderson Cancer Center, Houston, Texas 77030, USA
    Oncologist 18:525-32. 2013
    ..We also discuss how trial design can be improved, with the hope of increasing the number of drugs successfully developed to treat patients with neuroendocrine tumors...
  4. doi request reprint Everolimus in advanced pancreatic neuroendocrine tumors: the clinical experience
    James C Yao
    Departments of Gastrointestinal Medical Oncology and Surgical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA
    Cancer Res 73:1449-53. 2013
    ....
  5. pmc Evolving diagnostic and treatment strategies for pancreatic neuroendocrine tumors
    Matthew H Kulke
    Dana Farber Cancer Institute, Boston MA, USA
    J Hematol Oncol 4:29. 2011
    ....
  6. ncbi request reprint One hundred years after "carcinoid": epidemiology of and prognostic factors for neuroendocrine tumors in 35,825 cases in the United States
    James C Yao
    Department of Gastrointestinal Medical Oncology, Unit 426, The University of Texas M D Anderson Cancer Center, 1515 Holcombe Blvd, Houston, TX 77030, USA
    J Clin Oncol 26:3063-72. 2008
    ..Clinicians need to be become familiar with the natural history and patterns of disease progression, which are characteristic of these tumors...
  7. ncbi request reprint Clinicopathologic behavior of gastric adenocarcinoma in Hispanic patients: analysis of a single institution's experience over 15 years
    James C Yao
    Department of Gastrointestinal Medical Oncology, Unit 426, The University of Texas M D Anderson Cancer Center, 1515 Holcombe Blvd, Houston, TX 77030, USA
    J Clin Oncol 23:3094-103. 2005
    ..To determine the clinicopathologic behavior of gastric adenocarcinoma in Hispanics by comparing Hispanic and non-Hispanic patients treated at a single cancer center...
  8. doi request reprint Chromogranin A and neuron-specific enolase as prognostic markers in patients with advanced pNET treated with everolimus
    James C Yao
    Department of Gastrointestinal Medical Oncology, The University of Texas M D Anderson Cancer Center, 1515 Holcombe Boulevard, Box 426, Houston, Texas 77030, USA
    J Clin Endocrinol Metab 96:3741-9. 2011
    ..Chromogranin A (CgA) and neuron-specific enolase (NSE) are considered general biomarkers of these tumors...
  9. ncbi request reprint Clinical and in vitro studies of imatinib in advanced carcinoid tumors
    James C Yao
    Department of Gastrointestinal Medical Oncology, The University of Texas M D Anderson Cancer Center, Houston, Texas 77030, USA
    Clin Cancer Res 13:234-40. 2007
    ..Effective systemic therapy options for carcinoid tumors are lacking. We conducted in vitro studies and a phase II clinical trial to explore the activity of imatinib in carcinoid tumors...
  10. pmc Efficacy of RAD001 (everolimus) and octreotide LAR in advanced low- to intermediate-grade neuroendocrine tumors: results of a phase II study
    James C Yao
    Department of Gastrointestinal Medical Oncology, Unit 426, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Blvd, Houston, TX 77030, USA
    J Clin Oncol 26:4311-8. 2008
    ..Evaluate the activity of everolimus (RAD001) in combination with octreotide long-acting repeatable (LAR) in patients with advanced low- to intermediate-grade neuroendocrine tumors...
  11. ncbi request reprint Overcoming antiangiogenic resistance
    James C Yao
    Department of Gastrointestinal Medical Oncology, University of Texas, M D Anderson Cancer Center, Houston, Texas 77030, USA
    Clin Cancer Res 17:5217-9. 2011
    ..The very hypoxic stress produced by successful therapy may lead to upregulation of multiple pathways that promote angiogenesis and invasive behavior. Overcoming this evasive resistance may further improve outcome...
  12. doi request reprint Daily oral everolimus activity in patients with metastatic pancreatic neuroendocrine tumors after failure of cytotoxic chemotherapy: a phase II trial
    James C Yao
    Department of Gastrointestinal Medical Oncology, The University of Texas M D Anderson Cancer Center, 1515 Holcombe Blvd, Unit 426, Houston, TX 77030, USA
    J Clin Oncol 28:69-76. 2010
    ....
  13. pmc Population-based study of islet cell carcinoma
    James C Yao
    Department of Gastrointestinal Medical Oncology, The University of Texas M D Anderson Cancer Center, 1515 Holcombe Boulevard, Houston, Texas 77030, USA
    Ann Surg Oncol 14:3492-500. 2007
    ..We examine the epidemiology, natural history, and prognostic factors that affect the duration of survival for islet cell carcinoma by using population-based registries...
  14. doi request reprint Everolimus for advanced pancreatic neuroendocrine tumors
    James C Yao
    University of Texas M D Anderson Cancer Center, Houston, TX 77030, USA
    N Engl J Med 364:514-23. 2011
    ..We evaluated the agent in a prospective, randomized, phase 3 study...
  15. ncbi request reprint Molecular targeted therapy for neuroendocrine tumors
    James C Yao
    Departments of Gastrointestinal Medical Oncology, The University of Texas M D Anderson Cancer Center, Unit 426, 1515 Holcombe Boulevard, Houston, TX 77030, USA
    Hematol Oncol Clin North Am 21:575-81; x. 2007
    ..Preliminary results from phase II studies have shown promising results for VEGF and mTOR inhibitors in carcinoid and islet cell carcinoma and RET inhibitors in medullary thyroid carcinoma. Large confirmatory studies are planned...
  16. doi request reprint Targeting vascular endothelial growth factor in advanced carcinoid tumor: a random assignment phase II study of depot octreotide with bevacizumab and pegylated interferon alpha-2b
    James C Yao
    Department of Gastrointestinal Medical Oncology, Unit 426, The University of Texas M D Anderson Cancer, 1515 Holcombe Blvd, Houston, TX 77030, USA
    J Clin Oncol 26:1316-23. 2008
    ..Effective systemic therapy for advanced carcinoid is lacking. The combination of bevacizumab (BEV) and pegylated (PEG) interferon alpha-2b was evaluated among patients with metastatic or unresectable carcinoid tumors...
  17. pmc Combined treatment of pancreatic cancer with mithramycin A and tolfenamic acid promotes Sp1 degradation and synergistic antitumor activity
    Zhiliang Jia
    Department of Gastrointestinal Medical Oncology, The University of Texas M D Anderson Cancer Center, Houston, Texas 77030, USA
    Cancer Res 70:1111-9. 2010
    ....
  18. ncbi request reprint Hepatic arterial embolization and chemoembolization for the treatment of patients with metastatic neuroendocrine tumors: variables affecting response rates and survival
    Sanjay Gupta
    Section og Interventional Radiology, Department of Diagnostic Radiology, The University of Texas M D Anderson Cancer Center, Houston, Texas 77030 4009, USA
    Cancer 104:1590-602. 2005
    ....
  19. ncbi request reprint Allelic alterations in well-differentiated neuroendocrine tumors (carcinoid tumors) identified by genome-wide single nucleotide polymorphism analysis and comparison with pancreatic endocrine tumors
    Do Ha Kim
    Department of Pathology, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA
    Genes Chromosomes Cancer 47:84-92. 2008
    ..001). Our study shows that genome-wide allelotyping using SNP array is a powerful new tool for the analysis of allelic imbalances in WDNTs, and some of these alterations are tumor site-dependent and are different than in PETs...
  20. ncbi request reprint Multicenter phase II trial of S-1 plus cisplatin in patients with untreated advanced gastric or gastroesophageal junction adenocarcinoma
    Jaffer A Ajani
    Department of Gastrointestinal Medical Oncology, The University of Texas M D Anderson Cancer Center, Houston, TX 77030, USA
    J Clin Oncol 24:663-7. 2006
    ..We conducted a phase II multi-institutional trial, in the West, in patients with untreated advanced gastric or gastroesophageal junction adenocarcinoma to evaluate activity and safety of this combination...
  21. ncbi request reprint Drastic down-regulation of Kr├╝ppel-like factor 4 expression is critical in human gastric cancer development and progression
    Daoyan Wei
    Department of Gastrointestinal Medical Oncology, University of Texas M D Anderson Cancer Center, Houston, Texas 77030, USA
    Cancer Res 65:2746-54. 2005
    ..Collectively, our data provide first clinical and casual evidence and potential mechanism that the alteration of KLF4 expression plays a critical role in gastric cancer development and progression...
  22. ncbi request reprint Trimodality therapy without a platinum compound for localized carcinoma of the esophagus and gastroesophageal junction
    Jaffer A Ajani
    Department of Gastrointestinal Medical Oncology, The University of Texas M D Anderson Cancer Center, Houston, Texas, USA
    Cancer 116:1656-63. 2010
    ..It was hypothesized that chemoradiotherapy with fluoropyrimidine, taxane, and camptothecin would have preserved or improved efficacy with no compromise in safety...
  23. ncbi request reprint Elevated expression of vascular endothelial growth factor correlates with increased angiogenesis and decreased progression-free survival among patients with low-grade neuroendocrine tumors
    Jun Zhang
    Department of Gastrointestinal Medical Oncology, University of Texas M D Anderson Cancer Center, Houston, Texas 77030, USA
    Cancer 109:1478-86. 2007
    ..Vascular endothelial growth factor (VEGF) is a critical proangiogenic factor in solid tumors. However, its expression and role in human neuroendocrine tumor development and progression remains unclear...
  24. ncbi request reprint Expression of endothelial nitric oxide synthase correlates with the angiogenic phenotype of and predicts poor prognosis in human gastric cancer
    Liwei Wang
    Department of Gastrointestinal Medical Oncology, The University of Texas M D Anderson Cancer Center, Houston, TX 77030, USA
    Gastric Cancer 8:18-28. 2005
    ..We evaluated the expression of nitric oxide synthase (NOS) III and its relationship with the angiogenic phenotype and expression of the transcription factor Sp1, as well as their effect on survival in patients with gastric cancer...
  25. ncbi request reprint Antitumor activity of rapamycin and octreotide as single agents or in combination in neuroendocrine tumors
    Amy Moreno
    Department of Surgical Oncology, Division of Quantitative Sciences, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA
    Endocr Relat Cancer 15:257-66. 2008
    ..Further study is needed in order to determine whether octreotide or other somatostatin analogs enhance the efficacy of mTOR inhibitors in other models...
  26. doi request reprint Weekly docetaxel, cisplatin, and 5-fluorouracil as initial therapy for patients with advanced gastric and esophageal cancer
    Michael J Overman
    Department of Gastrointestinal Medical Oncology, The University of Texas M D Anderson Cancer Center, 1515 Holcombe Boulevard, Unit 426, Houston, TX 77030, USA
    Cancer 116:1446-53. 2010
    ..The objective of the current study was to evaluate the efficacy and tolerability of a weekly formulation of DCF...
  27. ncbi request reprint Risk factors associated with neuroendocrine tumors: A U.S.-based case-control study
    Manal M Hassan
    Department of Gastrointestinal Medical Oncology, The University of Texas M D Anderson Cancer Center, Houston, TX 77030, USA
    Int J Cancer 123:867-73. 2008
    ..The increased risk of gastric NETs in women with both diabetes and a positive family history of cancer suggest that women may have a greater genetic susceptibility to NETs than men...
  28. ncbi request reprint Epigenetic alterations in neuroendocrine tumors: methylation of RAS-association domain family 1, isoform A and p16 genes are associated with metastasis
    Lixia Liu
    Department of Pathology, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA
    Mod Pathol 18:1632-40. 2005
    ..044). Our study shows that in neuroendocrine tumors epigenetic alterations vary by tumor subsite and clinicopathologic features, including age of onset, histopathologic type and metastasis status...
  29. ncbi request reprint Expression of activated signal transducer and activator of transcription 3 predicts expression of vascular endothelial growth factor in and angiogenic phenotype of human gastric cancer
    Weida Gong
    Department of Neurosurgery, University of Texas M D Anderson Cancer Center, 1515 Holcombe Boulevard, Houston, TX 77030, USA
    Clin Cancer Res 11:1386-93. 2005
    ....
  30. ncbi request reprint A multi-center phase II study of sequential paclitaxel and bryostatin-1 (NSC 339555) in patients with untreated, advanced gastric or gastroesophageal junction adenocarcinoma
    Jaffer A Ajani
    Department of GI Medical Oncology, University of Texas, M D Anderson Cancer Center, 1515 Holcombe Blvd, Houston, TX 77030, USA
    Invest New Drugs 24:353-7. 2006
    ..Bryostatin-1 also increases cytotoxicity of paclitaxel in a sequential fashion. We studied sequential paclitaxel and bryostatin-1 in patients with untreated, advanced gastric adenocarcinoma...
  31. ncbi request reprint Effects of sex and racial/ethnic group on the pattern of gastric cancer localization
    James C Yao
    Department of Gastrointestinal Medical Oncology, Unit 426, The University of Texas M D Anderson Cancer Center, 1515 Holcombe Blvd, Houston, TX 77030, USA
    Gastric Cancer 5:208-12. 2002
    ..In Western countries, the overall incidence of gastric cancer is declining, while the incidence of proximal gastric cancer is rising. We evaluated the effect of sex, racial/ethnic group, and age on the localization of gastric cancer...
  32. ncbi request reprint Update on the management of neuroendocrine hepatic metastases
    David C Madoff
    Division of Diagnostic Imaging, Interventional Radiology Section, The University of Texas M D Anderson Cancer Center, 1515 Holcombe Boulevard, Unit 325, Houston, 77030 4009, USA
    J Vasc Interv Radiol 17:1235-49; quiz 1250. 2006
    ..This article reviews the care of patients with NETs and hepatic metastases, with emphasis on the increasingly important role of oncologic image-guided interventions...
  33. ncbi request reprint Hypomethylation of LINE-1 and Alu in well-differentiated neuroendocrine tumors (pancreatic endocrine tumors and carcinoid tumors)
    In Seon Choi
    Department of Pathology, The University of Texas MD Anderson Cancer Center, Houston, TX 77030 4095, USA
    Mod Pathol 20:802-10. 2007
    ....
  34. doi request reprint New strategies for advanced neuroendocrine tumors in the era of targeted therapy
    Mei Dong
    Department of Gastrointestinal Medical Oncology, The University of Texas M D Anderson Cancer Center, Houston, TX 77030, USA
    Clin Cancer Res 18:1830-6. 2012
    ..Development of rational combinations may further improve therapeutic outcome. These successes and our improved understanding of the underlying molecular biology are likely to lead to further important advances on the horizon...
  35. ncbi request reprint The development and characterization of a human midgut carcinoid cell line
    George van Buren
    Department of Surgical Oncology, The University of Texas M D Anderson Cancer Center, Houston, Texas 77230, USA
    Clin Cancer Res 13:4704-12. 2007
    ..The scarcity of good gastrointestinal NET models has limited the ability to study potential therapeutic agents. We describe and characterize the establishment of a human midgut carcinoid tumor cell line carcinoid tumor 2 (CNDT2)...
  36. ncbi request reprint Prognostic significance of CpG island methylator phenotype and microsatellite instability in gastric carcinoma
    Changhyeok An
    Department of Pathology, The University of Texas M D Anderson Cancer Center, 1515 Holcombe Boulevard, Houston, TX 77030 4096
    Clin Cancer Res 11:656-63. 2005
    ..The aim of this study was to evaluate the prognostic value of the CpG island methylator phenotype (CIMP) and microsatellite instability (MSI) in gastric cancer...
  37. ncbi request reprint Octreotide long-acting repeatable use among elderly patients with carcinoid syndrome and survival outcomes: a population-based analysis
    Chan Shen
    Department of Health Services Research, The University of Texas MD Anderson Cancer Center, Houston, Texas Department of Biostatistics, The University of Texas MD Anderson Cancer Center, Houston, Texas
    Cancer 120:2039-49. 2014
    ..To the authors' knowledge, the pattern of octreotide LAR use in clinical practice and its impact on survival outcomes has not been well documented...
  38. ncbi request reprint Allelic alterations in pancreatic endocrine tumors identified by genome-wide single nucleotide polymorphism analysis
    Yasuhiko Nagano
    Department of Pathology, MD Anderson Cancer Center, The University of Texas, 1515 Holcombe Boulevard, Box 85, Houston, Texas 77030 4095, USA
    Endocr Relat Cancer 14:483-92. 2007
    ..4 +/- 3.1 cm compared with 2.3 +/- 1.3 cm for low AI (P = 0.03). Our study shows that genome-wide allelotyping is a powerful new tool for the analysis of AI in PETs...
  39. ncbi request reprint Surgical treatment of non-functioning pancreatic islet cell tumors
    Maria A Kouvaraki
    Department of Surgical Oncology, The University of Texas M D Anderson Cancer Center, Houston, Texas, USA
    J Surg Oncol 89:170-85. 2005
    ..Treatment of metastatic disease includes biologic agents, cytotoxic chemotherapy, and liver-directed therapies...
  40. doi request reprint Yttrium-90 microsphere radioembolotherapy of hepatic metastatic neuroendocrine carcinomas after hepatic arterial embolization
    Ravi Murthy
    Division of Diagnostic Radiology, Section of Interventional Radiology, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA
    J Vasc Interv Radiol 19:145-51. 2008
    ..In this cohort, (90)Y microsphere radioembolization of neuroendocrine hepatic metastases was not precluded by previous nonradioactive embolization procedures, but the effectiveness in this population requires further investigation...
  41. ncbi request reprint Management of pancreatic endocrine tumors in multiple endocrine neoplasia type 1
    Maria A Kouvaraki
    Department of Surgical Oncology, The University of Texas M D Anderson Cancer Center, Unit 444, 1400 Holcombe Boulevard, Houston, Texas 77030 1402, USA
    World J Surg 30:643-53. 2006
    ..To help resolve this controversy, we retrospectively analyzed the clinical characteristics, surgical treatment, and clinical outcome of patients with MEN1-related PETs...
  42. ncbi request reprint Effect of timing of metastasis/disease recurrence and histologic differentiation on survival of patients with advanced gastric cancer
    Pooja R Patel
    Department of Gastrointestinal Medical Oncology, The University of Texas M D Anderson Cancer Center, Houston, Texas 77030, USA
    Cancer 110:2186-90. 2007
    ..It was hypothesized that survival would be similar...
  43. ncbi request reprint Use of research biopsies in clinical trials: are risks and benefits adequately discussed?
    Michael J Overman
    Department of Gastrointestinal Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA
    J Clin Oncol 31:17-22. 2013
    ..Although the incorporation of research biopsies into clinical trials is increasing, limited information is available about how study protocols and informed consents integrate and describe their use...
  44. ncbi request reprint Esophagectomy after concurrent chemoradiotherapy improves locoregional control in clinical stage II or III esophageal cancer patients
    Zhongxing Liao
    Department of Radiation Oncology, The University of Texas M D Anderson Cancer Center, Houston, TX 77030, USA
    Int J Radiat Oncol Biol Phys 60:1484-93. 2004
    ..To evaluate the effect of surgical resection on the outcome of patients with clinical Stage II or III cancer of the esophagus treated with concurrent chemoradiotherapy...
  45. ncbi request reprint Outcome of gastric cancer patients after successful gastrectomy: influence of the type of recurrence and histology on survival
    Pooja R Rohatgi
    Department of Gastrointestinal Medical Oncology, The University of Texas M D Anderson Cancer Center, Houston, Texas, USA
    Cancer 107:2576-80. 2006
    ..The effect of the location of disease recurrence after curative (R0) gastrectomy on patient survival has not been elucidated. The authors hypothesized that the location of recurrence would have a significant influence on survival...
  46. ncbi request reprint Fluorouracil, doxorubicin, and streptozocin in the treatment of patients with locally advanced and metastatic pancreatic endocrine carcinomas
    Maria A Kouvaraki
    Department of Surgical Oncology, The University of Texas M D Anderson Cancer Center, Houston, TX, USA
    J Clin Oncol 22:4762-71. 2004
    ....
  47. ncbi request reprint Association between expression of transcription factor Sp1 and increased vascular endothelial growth factor expression, advanced stage, and poor survival in patients with resected gastric cancer
    James C Yao
    Department of Gastrointestinal Medical Oncology, The University of Texas M D Anderson Cancer Center, Houston, Texas, USA
    Clin Cancer Res 10:4109-17. 2004
    ..Given the importance of Sp1 in the expression of VEGF, our data suggest that dysregulated Sp1 expression and activation play important roles in VEGF overexpression and, thus, gastric cancer development and progression...
  48. ncbi request reprint Hepatic artery embolization and chemoembolization for treatment of patients with metastatic carcinoid tumors: the M.D. Anderson experience
    Sanjay Gupta
    Department of Diagnostic Radiology, The University of Texas M D Anderson Cancer Center, Houston, Texas 77030, USA
    Cancer J 9:261-7. 2003
    ....
  49. ncbi request reprint Neuroendocrine tumors. Molecular targeted therapy for carcinoid and islet-cell carcinoma
    James C Yao
    Department of Gastrointestinal Medical Oncology, The University of Texas M D Anderson Cancer Center, Houston, TX 77030, USA
    Best Pract Res Clin Endocrinol Metab 21:163-72. 2007
    ..Encouraging results have been observed in studies with VEGF and mTOR inhibitors. Phase-III study of bevacizumab is planned in the US. Large-scale multinational phase-II and -III studies of everolimus are under way...
  50. ncbi request reprint Comparison of genetic alterations in neuroendocrine tumors: frequent loss of chromosome 18 in ileal carcinoid tumors
    Gordon G Wang
    Department of Pathology, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA
    Mod Pathol 18:1079-87. 2005
    ..02). Our study indicates that genetic alterations vary by tumor subsite and clinicopathologic features, and ileal carcinoid tumors have distinctive clinicopathologic and genetic profiles...
  51. ncbi request reprint Carcinoid tumors of the duodenum
    John T Mullen
    Department of Surgical Oncology, The University of Texas M D Anderson Cancer Center, Houston, TX 77030, USA
    Surgery 138:971-7; discussion 977-8. 2005
    ..Carcinoid tumors of the duodenum are rare, and their natural history has not been defined. Consequently, there is no consensus on the optimal extent of surgical treatment...
  52. ncbi request reprint Phase I pharmacokinetic study of S-1 plus cisplatin in patients with advanced gastric carcinoma
    Jaffer A Ajani
    Department of Gastrointestinal Medical Oncology, The University of Texas M D Anderson Cancer Center, Houston, TX 77030, USA
    J Clin Oncol 23:6957-65. 2005
    ..S-1 with cisplatin is considered highly active in Japanese gastric cancer patients. Therefore, we initiated a phase I pharmacokinetic study of this combination in our gastric cancer patients...
  53. doi request reprint Family history of cancer and associated risk of developing neuroendocrine tumors: a case-control study
    Manal M Hassan
    Department of Gastrointestinal Medical Oncology, Unit 426, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA
    Cancer Epidemiol Biomarkers Prev 17:959-65. 2008
    ..We evaluated the effect of positive family history of NET as well as other cancers on the development of NETs arising at five different locations...
  54. pmc Identification of cancer stem cells in human gastrointestinal carcinoid and neuroendocrine tumors
    Puja Gaur
    Department of Surgical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas 77230 1402, USA
    Gastroenterology 141:1728-37. 2011
    ..We sought to identify gastrointestinal neuroendocrine CSCs (N-CSCs) in surgical specimens and a NET cell line and to characterize novel N-CSC therapeutic targets...
  55. doi request reprint Perfusion CT findings in patients with metastatic carcinoid tumors undergoing bevacizumab and interferon therapy
    Chaan S Ng
    Department of Radiology, The University of Texas M D Anderson Cancer Center, Houston, 77030, USA
    AJR Am J Roentgenol 196:569-76. 2011
    ..The purpose of this article is to assess tumor changes on perfusion CT with bevacizumab and interferon (IFN) therapy in patients with metastatic carcinoid tumors and to evaluate perfusion CT differences between the two therapies...
  56. ncbi request reprint Neuroendocrine tumors: novel approaches in the age of targeted therapy
    Alexandria T Phan
    Gastrointestinal Medical Oncology, The University of Texas M D Anderson Cancer Center, Houston, Texas 77030, USA
    Oncology (Williston Park) 22:1617-23; discussion 1623-4, 1629. 2008
    ....
  57. ncbi request reprint Combined-modality therapy for gastric cancer
    James C Yao
    Department of Gastrointestinal Medical Oncology, University of Texas MD Anderson Cancer Center, Houston, Texas 77030, USA
    Semin Surg Oncol 21:223-7. 2003
    ..D. Anderson Cancer Center. The development of novel radioenhancers and the selection of therapy on the basis of molecular determinants of response may result in much-needed advances in this field...
  58. ncbi request reprint Thymic neuroendocrine tumors: a SEER database analysis of 160 patients
    Puja Gaur
    Department of Surgical Oncology, The University of Texas M D Anderson Cancer Center, Houston, TX 77030, USA
    Ann Surg 251:1117-21. 2010
    ..Due to the limited number of studies in the literature, very little is known about progress or trends made in the treatment and survival of patients with thymic NET...
  59. pmc Future directions in the treatment of neuroendocrine tumors: consensus report of the National Cancer Institute Neuroendocrine Tumor clinical trials planning meeting
    Matthew H Kulke
    Dana Farber Cancer Institute and Harvard Medical School, Boston, MA, USA
    J Clin Oncol 29:934-43. 2011
    ....
  60. doi request reprint Improving the success rate of gluteal intramuscular injections
    April E Boyd
    Department of Gastrointestinal Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA
    Pancreas 42:878-82. 2013
    ..This study aimed to improve the success rate of gluteal intramuscular (IM) injection...
  61. ncbi request reprint Venous tumor thrombus in nonfunctional pancreatic neuroendocrine tumors
    Aparna Balachandran
    Department of Diagnostic Radiology, University of Texas M D Anderson Cancer Center, Houston, TX 77030, USA
    AJR Am J Roentgenol 199:602-8. 2012
    ..We sought to determine the incidence of venous tumor thrombus in nonfunctioning pancreatic neuroendocrine tumors...
  62. ncbi request reprint Progesterone Receptor and PTEN Expression Predict Survival in Patients With Low- and Intermediate-Grade Pancreatic Neuroendocrine Tumors
    Jeannelyn S Estrella
    From the Departments of Pathology Drs Estrella, Broaddus, Wang, and Rashid, Immunology Ms Mathews, Biostatistics Ms Milton, and Gastrointestinal Medical Oncology, Dr Yao, The University of Texas MD Anderson Cancer Center, Houston, Texas
    Arch Pathol Lab Med 138:1027-36. 2014
    ..001). Conclusion.-Combined immunohistochemical assessment of PR and PTEN may help identify a small subset of PanNETs with more aggressive behavior and may aid in risk stratification. ..
  63. ncbi request reprint Adjuvant and preoperative chemotherapy for gastric cancer
    James C Yao
    Department of Gastrointestinal Oncology, The University of Texas M D Anderson Cancer Center, Box 426, 1515 Holcombe Boulevard, Houston, TX 77005 4341, USA
    Curr Oncol Rep 4:222-8. 2002
    ..Efforts to combine existing treatment modalities and new agents with novel mechanisms of action hold promise for the future...
  64. ncbi request reprint Carcinoid--a comprehensive review
    Isac I Schnirer
    Department of Gastrointestinal Oncology and Digestive Diseases, The University of Texas M D Anderson Cancer Center, Houston, Texas 77005 4341, USA
    Acta Oncol 42:672-92. 2003
    ..Early works in the area of tumor biology such as the role of p53, bcl-2, bax, MEN1, FGF TGF PDGF and VEGF expression are of interest and need to be explored further...
  65. doi request reprint mTOR inhibition, a potential novel approach for bronchial carcinoids
    Mei Dong
    Department of Gastrointestinal Medical Oncology, Unit 426, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Boulevard, Houston, Texas 77030, USA
    Endocr Relat Cancer 18:C15-8. 2011
    ..Although adding somatostatin analog to mTOR inhibitor did not provide a synergistic anti-tumor effect, development of rational combinations is highly warranted to further improve the outcome for patients with neuroendocrine tumors...
  66. ncbi request reprint Effect of pre-enhancement set point on computed tomographic perfusion values in normal liver and metastases to the liver from neuroendocrine tumors
    Chaan S Ng
    From the Departments of Diagnostic Radiology, Imaging Physics, The University of Texas MD Anderson Cancer Center, Houston, TX CT Research, GE Healthcare, Waukesha, WI Departments of Gastrointestinal Medical Oncology, and Biostatistics, The University of Texas MD Anderson Cancer Center, Houston, TX
    J Comput Assist Tomogr 38:526-34. 2014
    ..The objective of this study was to assess the effects of pre-enhancement set point (T1) positioning on computed tomographic perfusion (CTp) parameter values...
  67. doi request reprint The FGFR4-G388R single-nucleotide polymorphism alters pancreatic neuroendocrine tumor progression and response to mTOR inhibition therapy
    Stefano Serra
    Departments of Pathology, Campbell Family Institute for Cancer Research, University Health Network, Toronto, Ontario, Canada
    Cancer Res 72:5683-91. 2012
    ..Our findings highlight the importance of the FGFR4 allele in pNET progression and identify a predictive marker of potential therapeutic importance in this disease...
  68. ncbi request reprint Clinical burden of illness in patients with neuroendocrine tumors
    Gregory P Hess
    SDI, Plymouth Meeting, Philadelphia, PA 19462, USA
    Pancreas 41:1058-62. 2012
    ....
  69. doi request reprint Comparison of health-related quality of life in patients with neuroendocrine tumors with quality of life in the general US population
    Jennifer L Beaumont
    Department of Medical Social Sciences, Northwestern University Feinberg School of Medicine, Chicago, IL 60611, USA
    Pancreas 41:461-6. 2012
    ..The objective of this study was to evaluate the health-related quality of life (HRQL) burden of patients with neuroendocrine tumor (NET) and associations with demographic and clinical factors...
  70. ncbi request reprint Extended safety and efficacy data on S-1 plus cisplatin in patients with untreated, advanced gastric carcinoma in a multicenter phase II study
    Heinz Joseph Lenz
    Department of Medical Oncology, University of Southern California, Los Angeles, California, USA
    Cancer 109:33-40. 2007
    ....
  71. ncbi request reprint Primary and metastatic hepatic carcinoid: is there an algorithm?
    James C Yao
    Ann Surg Oncol 10:1133-5. 2003
  72. doi request reprint The impact of ethnicity on the presentation and prognosis of patients with gastric adenocarcinoma. Results from the National Cancer Data Base
    Waddah B Al-Refaie
    Division of Surgical Oncology, Department of Surgery, University of Minnesota and Minneapolis Veterans Affairs Medical Center, Minneapolis, Minnesota, USA
    Cancer 113:461-9. 2008
    ..To validate this observation in a large cohort, the authors of this report used the National Cancer Data Base (NCDB) to determine whether self-reported ethnicity influences presentation and survival in this patient population...
  73. ncbi request reprint Poorly differentiated carcinomas of the foregut (gastric, duodenal and pancreatic)
    Ola Nilsson
    Department of Pathology, Gothenburg University, Gothenburg, Sweden
    Neuroendocrinology 84:212-5. 2006